84
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Effect of plasmid-mediated stable interferon-γ expression on proliferation and cell death in the SKOV-3 human ovarian cancer cell line

, , &
Pages 498-503 | Received 21 Sep 2010, Accepted 25 Nov 2010, Published online: 12 Jan 2011
 

Abstract

Introduction: High interferon-γ (IFN-γ) expression in tumors has been reported to be a favorable prognostic marker. Continuous exposure of ovarian cancer cells to IFN-γ was previously shown to result in significant growth inhibition and apoptosis. Our goal in this study was to evaluate the effect of plasmid-mediated stable IFN-γ expression on the SKOV-3 human ovarian carcinoma cell line.

Methods: SKOV-3 cells were stably transfected with the pEGFP-IFN-γ plasmid. IFN-γ mRNA was detected by RT-PCR and IFN-γ protein expression was measured by ELISA. Proliferation and cell death in transfected SKOV-3 cells were measured by methyl-thiazolyl tetrazolium (MTT) assay and Hoechst 33258 staining, respectively and compared with untransfected and empty vector-transfected cells.

Results: pEGFP-IFN-γ SKOV-3 cells efficiently expressed and secreted IFN-γ. They exhibited significantly decreased cellular proliferation when compared with control untransfected or empty vector-transfected cells (P < 0.05). The mode of cell death was primarily apoptosis.

Conclusions: Stable expression of IFN-γ significantly inhibits the proliferation of ovarian carcinoma cells and has the potential to be used in clinical applications to treat ovarian carcinoma in the future.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.